Examples of using Dutasteride in English and their translations into Thai
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Product Name: Dutasteride.
Dutasteride/Avodart Specifications.
Product Name Dutasteride.
Dutasteride/Avodart Standard: Enterprise.
One capsule contains 500 μg of dutasteride.
Dutasteride/Avodart Appearance: White or almost white crystalline powder.
A causal relationship between taking dutasteride and the development of heart failure has not been established.
Dutasteride inhibits two of the three isoforms of 5-alpha reductase, I and II, whereas finasteride only inhibits type II, and has a much shorter half-life.
The analogue of Avodart is the Indian drug Duprost, the dosage of dutasteride in the capsule of which is also equal to 500 μg.
Since dutasteride can be absorbed through the skin, children and women should avoid contact with capsules whose integrity is compromised.
In those who are being regularly screened, 5-alpha-reductase inhibitors such as finasteride and dutasteride reduce the overall risk of being diagnosed with prostate cancer;
Dutasteride(trademark name Avodart) is a dual 5-α reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone DHT.
Most guys are splitting the dose into AM/PM, but that's not necessary. The half-life of dutasteride is very long- up to 5 weeks. So, you can dose it EOD(every other day) or longer if you wish.
Dutasteride(trademark name Avodart) is a dual 5-α reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone DHT.
Most guys are splitting the dose into AM/PM, but that's not necessary. The half-life of dutasteride is very long- up to 5 weeks. So, you can dose it EOD(every other day) or longer if you wish.
Dutasteride is useful for the symptoms of benign prostatic hyperplasia(BPH); colloquially known as an"enlarged prostate". In those who are being regularly screened 5-alpha-reductase inhibitor(finasteride and dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
While the potential for positive, negative or neutral changes to the potential risk of developing prostate cancer with dutasteride has not been established, evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer.
Dutasteride is useful for the symptoms of benign prostatic hyperplasia(BPH); colloquially known as an"enlarged prostate". In those who are being regularly screened 5-alpha-reductase inhibitor(finasteride and dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
The primary area for concern is for patients who may develop prostate cancer whilst taking dutasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.
The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific reduction of nandrolone action, considerably increasing the tendency of nandrolone to produce androgenic side effects. Reductase inhibitors should be avoided with nandrolone if low androgenicity is desired.
The concurrent use of a 5- alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific reduction of nandrolone action, considerably increasing the tendency of nandrolone to produce androgenic side effects. Reductase inhibitors should be avoided with nandrolone if low androgenicity is desired.
Unlike triple inhibitors of all three isoenzymes of 5α-reductase like dutasteride which can reduce DHT levels in the entire body by more than 99%, finasteride does not completely suppress DHT production because it lacks significant inhibitory effects on the 5α-reductase type I isoenzyme, with 100-fold less affinity for I as compared to II.